ÀÚ·á¹®ÀÇ:02-703-5000/info@oic.co.kr        
À¯ÀüÀÚ Áúº´&Ä¡·á ¹é½Å ³­¿¬Á¦ IT ¹× »çÀ̹ö º¸¾È ȯ°æ¹®Á¦ ¹Ì¿ë/¼ºÇü ÀÚµ¿Â÷ À¶ÇÕ/¹Ì·¡»ê¾÷ ÀçÈ°¿ë Áö¿À¸Åƽ½º/ÅÚ·¹¸Åƽ½º ž翭 ¿¡³ÊÁö ¹ÙÀÌ¿À¸ÞÄ«Æ®·Î´Ð½º Á¢ÂøÁ¦&Á¡ÂøÁ¦ ÄÚÆà ¿þ¾î·¯ºí ÀåÄ¡,±â±â »ö¼Ò,¾È·á,¿°·á »ýÈ­ÇÐ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ¼ö·Â¹ßÀü ±×¸°¿¬·á/¹ÙÀÌ¿À¿¬·á üÁß°ü¸®/ºñ¸¸Ä¡·á dz·Â ¿¡³ÊÁö Àü·Â¹ÝµµÃ¼ ÀÇ¾à °ü·Ã ¹«¿ª,Àü·« ½º¸¶Æ®È¨&½º¸¶Æ®ºôµù Æó±â¹° ó¸® ³ÃÀå°í È­ÇÐÇ° ±ÔÁ¦ Ä«¸Þ¶ó ¾ËÃ÷ÇÏÀ̸Ó/Ä¡¸Å/ÆÄŲ½¼ ·Îº¿ »ê¾÷ ¼¾¼­ Ä¡°ú¿ë ±â±â ¾È°ú¿ë ±â±â °íÁÖÆÄ, ¹«¼± ÁÖÆļö Flexible display ÀǾàÇ° Á¦Á¶±â¾÷ ÀÇ·á¿ë/¹ÙÀÌ¿À ÀÎÆ÷¸Åƽ½º »ýüÀç·á/»ýüÈí¼ö »ýü¸ð¹æ/»ýŸð¹æ ¹ÙÀÌ¿À¸â½º/¹ÙÀÌ¿À³ª³ë
all of these words any of these words
 
    Àΰ£ÀÇ °¨¼º¿¡ °¡±î¿î...
    ¹Ì·¡ ¿¹Ãø¿¡ ÀÇÇÑ ¿¬...
    ÀÚµ¿Â÷ ½Ç³»ÀÇ Á¤¼÷¼º...
    ±Ý¼Ó ³ª³ë ÀÔÀÚ, ¹Ì¸³...
    ** ÇÒÀÎÀÚ·á Àüü
 
***************************
Àüü  |  ¿µ¹®¸¸  |  ÀϹ®¸¸      Èñ±ÍÁúȯ
(ÁÖÁ¦¿Í °ü·Ã¾øÀ¸¸é "»õ·Î°íħ" ÇØÁÖ¼¼¿ä)
 
ÀÚ·á¸í   °¡°Ý ¹ßÇàÀÏ
2012-2013 Á¦³×¸¯ ÀǾàÇ°¡¤Àå±â ¼öÀçÇ°(¼±¹ß ÀǾàÇ°) µ¥ÀÌÅÍ ºÏ No.1 ±â¾÷Æí    ¡Í 140,000   2012-11
Generic Drugs: World Market Outlook 2011-2021(¼¼°è Á¦³×¸¯ ¾àÇ° ½ÃÀå)    ¡Ì 1,549   2012-11
Èñ¼Ò Áúȯ/³­Ä¡º´ ÀÇ Áø´Ü¡¤Ä¡·á¿Í Á¦Ç° °³¹ß    ¡Í40,000 ÇÒÀΰ¡ ¡Í 95,000   2012-10
Profound Research and Investment Prospect of China¡¯s Generic Drug Market, 2012-2016(Áß±¹ÀÇ Á¦³×¸¯ ÀǾàÇ° ÅõÀÚ ¿¹»ó ½ÃÀå)    $ 1,800   2012-08
Èñ¼Ò Áúº´¾àÀÇ ±Û·Î¹ú °³¹ß 2012    ¡Í 95,000   2012-07
Top 194 Generic Pharmaceuticals (Global)(Àü¼¼°è ÁÖ¿ä 194 Á¦³×¸¯ ÀǾàÇ°)    ¡Ì 950   2012-07
Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making(ÀǾàÇ° ÆÄÀÌÇÁ¶óÀÎ ÀçÆò°¡ - ÇâÈÄ ÀÇ»ç°áÁ¤À» Çü¼ºÇÏ´Â ½ÅÈï ½ÃÀå, »ý¹°Á¦Á¦ ¹× Èñ±ÍÀǾàÇ°)    $ 3,500   2012-06
Generic Defense Strategies(Á¦³×¸¯ µðÆ潺 Àü·«)    $ 3,835   2012-05
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer strong Opportunities for Investment and Licensing Activity(À¯Àü¼º Èñ±ÍÁúȯ Ä¡·á : ³¶Æ÷¼º ¼¶À¯Áõ(CF) ½Å¹°ÁúÀÌ Á¦°øÇÏ´Â °­·ÂÇÑ ÅõÀÚ ±âȸ ¹× ¶óÀ̼¾½Ì È°µ¿)    $ 3,500   2012-05
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution(½ÉÇ÷°ü Áúȯ¿ë Á¦³×¸¯ ÀǾàÇ° ½ÃÀå)    $ 3,500   2012-05
Orphan Diseases Therapeutics in CNS to 2017-Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington¡¯s Disease Segment(ÁßÃ߽Űæ°è Èñ±ÍÁúȯ Ä¡·á ½ÃÀå)    $ 3,500   2012-04
Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022(ÀǾàÇ° ¸®´õ ½Ã¸®Áî : ÁÖ¿ä 50 Á¦³×¸¯ ¾àÇ° Á¦Á¶»ç)    ¡Ì 1,699   2012-03
Neurometabolic Disorders Market to 2017 - Novel therapies for Rare Diseases Such As Gaucher and Niemann-Pick Poised to Supersede Existing Therapies(½Å°æ´ë»ç Àå¾Ö ½ÃÀå)    $ 3,500   2012-03
Japan Generics Market Analysis(ÀϺ»ÀÇ Á¦³×¸¯ ÀǾàÇ° ½ÃÀåºÐ¼®)    $ 1,000   2012-02
Generic Pharmaceuticals Industry(Á¦³×¸¯ ÀǾàÇ° »ê¾÷)    ¡Ì 950   2012-01
      

1  2  3  4  5  6  7  8  9  
 

 

±Ý¿¬Ä¡·áÁ¦
Èñ±ÍÁúȯ
Å°³ª¾ÆÁ¦
Á¦³×¸¯ ÀǾàÇ°
¹æ»ç¼º ÀǾàÇ°
ó¹æ¾à
¹ÙÀÌ¿ÀÀǾà
»ý¾à,Çѹæ,¾àÃÊ
ÁÖ»çÁ¦
ÀÇ·á¿ë ¸¶¾à ¹× ´ë¸¶
Åë½Å
ÀüÀÚ
Áß°ø¾÷
Á¦¾à
È­ÇÐ
ÀÇÇÐ
ȯ°æ
½ÄÇ°
¹æÀ§»ê¾÷
±âŸ
   .
   -¿¬±¸°³¹ß¸®´õ .
   -CosmeticStage .
   -PharmStage .
   -MaterialStage .
   -Â÷Àç Technology .
   .
   .
   .
ID(email)
Password
ºñ¹Ð¹øÈ£ ºÐ½Ç ȸ¿ø°¡ÀÔ
È­Æó
ȯÀ²
(ÇϳªÀºÇà ¼Û±Ýº¸³¾¶§)
¹Ì±¹USD
\ 1,397.60
ÀϺ»JPY
\ 9.0396
À¯·ÎEUR
\ 1,487.19
¿µ±¹GBP
\ 1,737.29

Copyright¨Ï2024 OIC(Overseas Information Center) All Rights Reserved.
04373 ¼­¿ï½Ã ¿ë»ê±¸ ÀÌÃÌ·Î 1(GSÇÑ°­¿¡Å¬¶óÆ®) 1121È£
E_mail : info@oic.co.kr Tel: 02-703-5000 Fax: 02-714-1109 /°³ÀÎÁ¤º¸ Ãë±Þ¹æħ